Fri 11/12/2021 12:02 PM
Goldman Sachs’ Private Credit division is backing the acquisition of French producer of pharmaceutical hyaluronic acid HTL Biotechnology with a €500 million cov-lite unitranche facility based on 7x leverage and 2x PIK debt, sources told Reorg.
To view the relevant documents linked as well as our EMEA Middle Market team's coverage of thousands of other stressed/distressed debt situations including our Goldman Sachs HTL Biotechnology acquisition analysis, request a trial here:
This article is an example of the content you may receive if you subscribe to a product of Reorg Research, Inc. or one of its affiliates (collectively, “Reorg”). The information contained herein should not be construed as legal, investment, accounting or other professional services advice on any subject. Reorg, its affiliates, officers, directors, partners and employees expressly disclaim all liability in respect to actions taken or not taken based on any or all the contents of this publication. Copyright © 2024 Reorg Research, Inc. All rights reserved.